Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic ER+ Her2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05577923
What this trial is testing

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Who this might be right for
Metastatic Breast Cancer
Fudan University 126
Early research (Phase 1)WithdrawnNCT01333423
What this trial is testing

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Study completedNCT00553358
What this trial is testing

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 455
Testing effectiveness (Phase 2)Looking for participantsNCT06263543
What this trial is testing

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Who this might be right for
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+2 more
Reshma L. Mahtani, D.O. 75
Testing effectiveness (Phase 2)Study completedNCT00371345
What this trial is testing

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Who this might be right for
Breast CancerMetastasis
Bristol-Myers Squibb 92
Testing effectiveness (Phase 2)Looking for participantsNCT05933395
What this trial is testing

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Who this might be right for
Advanced Breast Cancer
Dartmouth-Hitchcock Medical Center 135
Testing effectiveness (Phase 2)Study completedNCT02648477
What this trial is testing

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
City of Hope Medical Center 30
Testing effectiveness (Phase 2)UnknownNCT04194684
What this trial is testing

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chinese Academy of Medical Sciences 108
Testing effectiveness (Phase 2)Looking for participantsNCT05573126
What this trial is testing

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Who this might be right for
Hormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast Cancer
Ellipses Pharma 95
Testing effectiveness (Phase 2)Study completedNCT02954055
What this trial is testing

MEtronomic TrEatment Option in Advanced bReast cAncer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 140
Not applicableStudy completedNCT04276272
What this trial is testing

D4 Choline Breast PET/CT

Who this might be right for
HER2-negative Breast CancerER Positive Breast CancerMetastatic Breast Cancer
Imperial College London 6
Testing effectiveness (Phase 2)Study completedNCT04072952
What this trial is testing

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Arvinas Estrogen Receptor, Inc. 217
Large-scale testing (Phase 3)Ended earlyNCT01303679
What this trial is testing

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Who this might be right for
First Line Metastatic Breast Cancer
ARCAGY/ GINECO GROUP 117
Early research (Phase 1)Study completedNCT05501769
What this trial is testing

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

Who this might be right for
Breast Cancer
Arvinas Estrogen Receptor, Inc. 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT06206837
What this trial is testing

Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Pfizer 71
Testing effectiveness (Phase 2)Study completedNCT02188745
What this trial is testing

ER Reactivation Therapy for Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Dartmouth-Hitchcock Medical Center 20
Not applicableLooking for participantsNCT07563595
What this trial is testing

Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
iOMEDICO AG 500
Testing effectiveness (Phase 2)WithdrawnNCT01361945
What this trial is testing

AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHER-2 Positive Breast Cancer+1 more
Texas Tech University Health Sciences Center, El Paso
Large-scale testing (Phase 3)Active Not RecruitingNCT06760637
What this trial is testing

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Who this might be right for
Breast Cancer
Pfizer 1,035
Early research (Phase 1)Ended earlyNCT07214662
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 3
Next Page